

Enabling a Healthier World
www.lonza.com

Lonza
Biologics

GS Discovery® Transient Expression System

Why settle for less, when GS Discovery® gives you more?

High transient titers and so much more
With increasing pressure on timelines to get novel biologics to market, the demand for a high performing transient expression system has never been greater.

With faster timelines than stable pool or stable cell line construction, transient expression is typically used for material generation in early stage therapeutic development.

Speed up therapeutic candidate selection with higher transient titers delivered in shorter timelines,* save money with cost effective reagents, streamline your journey to market by using the same proven CHO cell line and vectors from discovery through to commercial production.

	GS Discovery® system	Third party off-the-shelf transient kit
The same cell line and vectors from discovery through to commercial	+	–
Cost effective reagents	+	–
High transient titers	+	+
Demonstrated PQA (product quality attributes) comparability from transient to stable	+	–
Personalised technical and regulatory support	+	–

Flexibility to meet your needs

Requirements for therapeutic protein expression may differ at earlier or later development stages. At earlier stages, where the emphasis is typically on speed, the titers offered by traditional transient processes may be sufficient to meet material needs. For the most promising candidates, however, often more extensive testing is performed and thus greater quantities of product are required.

The GS Discovery® system offers two optimised transient expression processes for flexibility, both leveraging our industry-recognised CHOK1SV GS-KO® cell line and GSquad® vectors (Figure 1). These cells and vectors are also proven for stable processes and scaled-up production, so there is no need to switch your expression system later in development.

The standard GS® transient process is a traditional transient expression protocol, and prioritises rapid material supply.

The GS piggyBac® transient process is a novel hybrid process that merges the benefits of transient (shorter timelines) and stable (high titer) expression processes. How does it work? This process is powered by Lonza's GS piggyBac® transposon technology to reach the highest transient titers.



Figure 1. GS Discovery® offers flexibility to prioritise speed or the highest titers, depending on your needs. Data shows transient expression of an IgG1 monoclonal antibody.

Contact us

Scan or click the QR code to read the white paper.
To learn more, contact us at **licensing@lonza.com**
Visit the website page for the GS Discovery® Transient Expression Platform at **www.lonza.com/biologics/expression-technologies/gs-discovery**

High titers for a broad range of molecules

In the GS Discovery® GS piggyBac® transient process, Lonza's GS piggyBac® transposon technology is leveraged to insert the DNA into the cell genome, preferentially targeting stable regions of the genome associated with highly expressed genes. This boosts transient titers, rivaling leading off-the-shelf kits, in one system that can take you from discovery to commercial production. (Figure 2).



Figure 2. High transient titers that rival leading third party off-the-shelf kit.

We've got your back

GS Discovery® is accessible via a license. With our Lonza in Your Lab® offering, a license agreement with us means that you have access to:

- Extensive know-how in our online GS® portal
- Free upgrades through continual product innovation**
- Our network of protein expression experts who can support you at all stages in your therapeutic development journey

*Compared to Lonza's legacy transient transfection process
**Subject to the terms and conditions of the license agreement

Lonza Edition No. 04-2024